PALO ALTO, Calif., April 23 /PRNewswire/ -- Percutaneous Systems, Inc. (PercSys) today announced that it will introduce the Accordion CoAx(TM) Stone Control Device, the newest member of its Accordion family of disposable kidney stone treatment tools, at the upcoming annual meeting of the American Urological Association (AUA), to be held April 25-28 in Chicago, Illinois.
The Accordion CoAx Stone Control Device is an over-the-wire stone management device designed to simplify and shorten minimally invasive percutaneous kidney stone procedures, called percutaneous nephrolithotomy (PCNL). A method of stone removal that involves passing small endoscopic instruments through the skin into the kidney, PCNL is the treatment of choice for patients with large kidney stones or for those with complex, irregularly shaped “staghorn” stones.
During the PCNL procedure, the Accordion CoAx Stone Control Device is deployed in the upper portion of the ureter, a tube that carries urine from the kidney to the bladder. The low-profile Accordion CoAx device is placed over a guidewire, and once in position, forms a proprietary multi-fold, 15 millimeter diameter film occlusion that conforms to and fills the ureter in order to prevent the migration of stone fragments further down in the ureter during the fragmentation procedure. In this way, the CoAx device can eliminate or minimize the need for an additional procedure.
“The Accordion CoAx Stone Control Device combines the benefits of the original PercSys Accordion device with the versatility of an over-the-wire design,” said Mantu Gupta MD, Director of the New York-Presbyterian Kidney Stone Center and the Director of Endourology, New York Presbyterian Hospital/Columbia University, New York, NY. “Optimized for PCNL procedures, the new CoAx device builds on the original Accordion platform, which has been clinically proven to reduce procedural time and decrease morbidity during PCNL treatments at our institution.”
“We have found the Accordion CoAx Stone Control Device to be a valuable tool during PCNL procedures, as it both facilitates retrograde contrast injections for diagnosis and renal targeting as well as prevents antegrade fragment migration into the ureter,” said Demetrius H. Bagley MD, Nathan Lewis Hatfield Professor of Urology, Thomas Jefferson University Hospital, Philadelphia, PA. “Unlike other catheters used for this purpose, the Accordion CoAx device, thanks to its occlusion-film design, does not move from the treatment location despite the patient handling inherent in PCNL procedures.”
The Accordion CoAx Stone Control Device joins the currently available 7mm and 10mm PercSys Accordion(R) Stone Management Devices, which are used during ureteroscopic lithotripsy procedures to prevent the retrograde migration of stone fragments into the kidney. The 7mm and 10mm Accordion Stone Management Devices have been used in nearly 1,400 procedures since their introduction in 2007 and 2008, respectively.
About Kidney Stones
Approximately 1.7 million people in the U.S. experience kidney stones each year. Half of those will have at least one recurrence during their lifetime. One in four will find it necessary to undergo endoscopic lithotripsy (PCNL or ureteroscopic stone treatment). Once primarily a male affliction, kidney stone disease is increasingly affecting women, who now constitute two of every five cases diagnosed.
About PercSys
PercSys is a medical device company focused on providing a suite of single-use tools to improve every type of kidney/ureteral stone treatment in every location within the urinary tract. The company’s goal is to make endourologic kidney stone procedures easier, less traumatic, and more effective therapeutically. PercSys currently markets the 7 and 10mm PercSys Accordion Stone Management Devices and will commercially launch the Accordion CoAx Stone Control Device in mid-2009. In addition to providing devices for procedures in the operating room, the company is developing additional products and techniques for both external shock-wave stone treatments and for office-based stone interventions. For more information, contact PercSys at 1-650-493-4200, or visit its website at www.percsys.com.
Note: Product photo available upon request.
CONTACT: Craig Ball, Vice President, Marketing, PercSys, +1-650-493-4200,
ext. 207, CBall@PercSys.com; or Carole Melis, CLM Communications,
+1-650-342-5686, clmcomm1@gmail.com, for PercSys
Web site: http://www.percsys.com/
